Drug Discovery & Nutraceuticals
Canvax has built a unique ecosystem of Excellency for drug discovery and development, to cover unmet clinical needs in disorders such as cancer and central nervous system diseases. It is supported by a worldwide expert network in disease target validation, screening of novel molecular libraries against both kinases and GPCRs, medicinal chemistry, in vitro and in vivo studies, ADME and toxicology studies.
One patented lead molecule, Bozinib, is already in preclinical research and has shown promising properties as anticancer agent, specifically against cancer stem cells, the resistant core of cancers. Three more programs are ready to enter the drug discovery phase using Canvax´s exclusive screening patented platform, FRIDAGPCR, a robust cell-based homogeneous assay validated for cancer and central nervous system GPCRs.
FRIDAGPCR screening technology allows us to outline a diversified pipeline of innovative drugs.
Oxidative stress is a common hallmark of several neurological diseases like Alzheimer, Parkinson, Schizophrenia, Multiple Sclerosis and Huntington diseases, and the imbalance in the oxidation-reduction equilibrium is also related to the pathogenesis of Cardiovascular Disease and Metabolic Syndrome.
Canvax, in collaboration with IMIBIC (Córdoba, Spain), have developed a patented formulation from a vegetal source that ameliorates significantly oxidative stress in an animal model of Multiple Sclerosis. In addition, Canvax´s Scientists have developed a process that improves 14-fold the yield of the active molecule, when compared to the best industrial process used today, and such process is also being patented.
Canvax is carrying the human Proof-of-Concept (PoC) for the value of the product as a functional ingredient. It is expected to begin commercialisation by late 2016.